ArriVent BioPharma (AVBP) Depreciation & Amortization (CF) (2026)
ArriVent BioPharma's (AVBP) quarterly Depreciation & Amortization (CF) came in at -$559000.0 in Q1 2026.
ArriVent BioPharma (AVBP) Depreciation & Amortization (CF) (2026) Analysis & Trends
ArriVent BioPharma has disclosed Depreciation & Amortization (CF) across 1 years of filings, most recently posting -$559000.0 for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at -$559000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$559000.0 (changed N/A YoY), and the FY2025 annual result was -$3.0 million, changed N/A from the prior year.
- Depreciation & Amortization (CF) came in at -$559000.0 for Q1 2026 at ArriVent BioPharma.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of -$559000.0 in Q1 2026 to a low of -$559000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | ArriVent BioPharma | 1.37 Bn | 1.37 Bn | - | -559,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -559,000.00 |
| Mar 31, 2026 | -559,000.00 |